Follow this innovation
[ via 
] [?]
A New Generation of Potent Adjuvants
Schepens Eye Research Institute
posted on 03/04/2009
Adjuvants such as alum are used in vaccination to promote the immune response. The bacterial-based adjuvants augment antigen-presenting cell activity to enhance the immunogenicity of the vaccine, but such adjuvants cause severe inflammatory reactions. Specific neuropeptides found in the eye modulate innate and adaptive immunity and can be used to promote immunity associated with vaccination and to minimize the side-effects of immunization. The combination of a neuropeptide with an immunogen modifies the immune response to the immunogen according to the specific need: induction or suppression of vaccine induced inflammation or specific cellular immunity. The technology finds applications in vaccination, immunotherapy and in the development of treatments against autoimmune diseases.
File Number: SERI-145
Other Information:
Investigator(s)
Ph.D. Andrew Taylor
Contact
Mary Chatterton, Director of Corporate Alliances. mary.chatterton@schepens.harvard.edu.
This innovation currently is not available for online licensing. Please contact the case manager at Schepens Eye Research Institute for more information.
request more info
ProfileFind more innovations
